首页> 外文期刊>Archives of clinical infectious diseases. >Intravenous Immunoglobulin for Treatment of Patients with COVID-19: A Case-control Study
【24h】

Intravenous Immunoglobulin for Treatment of Patients with COVID-19: A Case-control Study

机译:用于治疗Covid-19患者的静脉内免疫球蛋白:案例对照研究

获取原文
           

摘要

Background: It seems that the risk of developing complications associated with coronavirus disease 2019 (COVID-19) is higher among individuals with weakened immune systems. Objectives: Therefore, this study was carried out to determine the effectiveness of intravenous immunoglobulin (IVIG) for the treatment of patients not entering the intubation phase compared to those entering the intubation phase. Methods: This descriptive case-control study was performed on 26 patients with COVID-19 referring to Imam Reza hospital in Mashhad, Iran, in March 2020. For subjects with COVID-19 not responding to the standard three-drug protocol (i.e., ribavirin, hydroxychloroquine, and lopinavir/ritonavir), three doses of IVIG (0.4 g/kg/day) were added to the protocol. The patients were divided into two groups of subjects not entering the intubation phase and those entering the intubation phase and compared in terms of different variables. Results: The comparison of laboratory findings showed a significant difference before and after receiving IVIG regarding oxygen saturation (P 0.005), white blood cell (P = 0.001), hemoglobin level (P = 0.0002), lymphocyte count (P = 0.03), and C-reactive protein (P = 0.001). In general, 53.8% and 46.2% of the patients were discharged and expired, respectively. All the subjects not entering the intubation phase were recovered; nevertheless, only one case entering the intubation phase was recovered, and 92.3% of the patients expired. A significant difference was observed between the patients not entering the intubation phase and those entering the intubation phase in terms of mortality (χ2 = 22.28; P 0.005). Conclusions: In summary, the obtained results of the current study confirmed the therapeutic effects of IVIG on patients with COVID-19. Moreover, better treatment results, shorter hospital stay, and lower mortality rates were observed among COVID-19 patients who did not enter the intubation phase in comparison with those entering the intubation phase.
机译:背景:似乎患有冠状病毒疾病2019(Covid-19)相关的并发症的风险较弱,免疫系统弱化。目标:因此,该研究进行了与进入插管阶段的人相比,确定静脉内免疫球蛋白(IVIG)治疗未进入插管阶段的患者的有效性。方法:在2020年3月,在Mashhad的26例Covid-19患者中对伊朗Mashhad的IMAM Reza医院进行了这项描述性案例对照研究。对于Covid-19没有响应标准的三种药物协议(即利巴韦林的科目,羟基氯喹和洛诺维尔/ ritonavir),将三个剂量的IVIg(0.4g / kg /天)加入到方案中。将患者分为两组未进入插管阶段的受试者,并且在不同的变量方面比较了插管阶段的那些受试者。结果:实验室发现的比较在接受IVIG关于氧饱和度(P <0.005),白细胞(P = 0.001),血红蛋白水平(P = 0.0002),淋巴细胞计数(P = 0.03)之前和之后的比较显示出显着差异和C反应蛋白(p = 0.001)。一般而言,53.8%和46.2%的患者分别排出并过期。恢复了未进入插管阶段的所有受试者;然而,回收了一个进入插管阶段的一个案例,92.3%的患者已过期。在没有进入插管阶段的患者之间观察到显着差异,并且在死亡率方面进入插管阶段的患者(χ2= 22.28; p <0.005)。结论:总之,目前研究的结果证实了IVIG对Covid-19患者的治疗效果。此外,在与进入插管阶段的人相比,在Covid-19患者中观察到更好的治疗结果,较短的住院住宿和降低死亡率,以及未进入插管阶段的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号